Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viatris Inc (NQ: VTRS )

9.625 -0.425 (-4.23%)
Streaming Delayed Price Updated: 3:56 PM EDT, Oct 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 16,618,130
Open 9.920
Bid (Size) 9.620 (100)
Ask (Size) 9.630 (286)
Prev. Close 10.05
Today's Range 9.360 - 9.930
52wk Range 8.460 - 12.40
Shares Outstanding 1,212,301,241
Dividend Yield 4.99%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Obesity Drug Wegovy's Triumph to Catapult Novo Holdings In Golden Era Of Wealth Boost
Novo Holdings, the controlling shareholder of Novo Nordisk A/S (NYSE: NVO), is bracing for a significant influx of capital stemming from the thriving success of the weight-loss drug Wegovy.  
Via Benzinga
'Airbnb Has Foundational Cracks', Disney+ Follows Netflix On Subscription Sharing Crackdown, Microsoft's Nadella Criticizes Google's Exclusive Content Deals: Today's Top Stories
Benzinga 
Via Benzinga

Performance

YTD
-15.42%
-15.42%
1 Month
-9.37%
-9.37%
3 Month
-2.68%
-2.68%
6 Month
+0.16%
+0.16%
1 Year
+10.38%
+10.38%

More News

Read More
Novo Nordisk Weight Loss Drug Patent Battle Against Viatris - Emerges As Winner
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Viatris Stock Bounds Higher As Divestitures Reach Nearly $7 Billion
Via Investor's Business Daily
Viatris Stock: Bear vs. Bull
Via The Motley Fool
Better High-Yield Dividend Stock: Takeda Pharmaceutical vs. Viatris
Via The Motley Fool
Where Will Viatris Be in 5 Years?
Via The Motley Fool
Viatris Phase 1 Asset Divestiture Story: Plans To Sell Certain OTC Products, Women's Healthcare Business & More
Via Benzinga
Could Viatris Stock Help You Become a Millionaire?
Via The Motley Fool
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields
Via Benzinga
Despite Efforts, Vulnerable Patients Still Face Barriers to Essential Medicines, Says New Report
Via Benzinga
NASDAQ: VTRS Shareholder Notice Investigation over Potential Wrongdoing by Certain Directors of Viatris Inc.
Via SBWire
2 Beaten-Down Dividend Stocks to Buy
Via The Motley Fool
Is Viatris Stock Good for Dividend Income?
Via The Motley Fool
A Preview Of Viatris's Earnings
Via Benzinga
'Stocks In Monopolistic Bull Market': Wall Street Analyst Contemplates A Bright Future For Next Phase
Via Benzinga
Want to Collect $500 in Dividends Every Month? Invest $90,000 in These 3 Stocks
Via The Motley Fool
3 Pharmaceutical Stocks That Are Too Cheap to Ignore
Via The Motley Fool
CVS Health Just Created a New Problem For Viatris. Here's What You Need to Know
Via The Motley Fool
VIATRIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Viatris Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Viatris Could Soon Make a Generic Ozempic, But Does That Make It a Buy?
Via The Motley Fool
If You'd Invested $25,000 in Viatris in 2020, This Is How Much You Would Have Today
Via The Motley Fool
Topics Stocks
Exposures US Equities
Viatris Q2 Earnings Beat Estimates, Multiple Sclerosis Therapy Accepted For FDA Review
Via Benzinga
Elanco Animal Health, Sovos Brands, Veritiv, Graham And Other Big Stocks Moving Higher On Monday
Via Benzinga
Want $1,500 in Annual Passive Income? Invest This Much in Viatris Stock Each Month for 5 Years
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.